Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

Launched by CARMOT AUSTRALIA FIRST PTY LTD · Apr 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CT-996 for people who are overweight or obese and have type 2 diabetes. The main goal of the study is to see if this treatment is safe to use and how it works in the body. The trial is currently looking for participants aged 18 to 65 who have a body mass index (BMI) between 25 and 40 and have maintained a stable weight for the past two months.

If you decide to participate, you will undergo various assessments to monitor your health and how your body responds to the treatment. It’s important to note that people with serious medical conditions, uncontrolled high blood pressure, or a recent history of substance abuse may not be eligible to join. This trial is a first step in understanding how CT-996 might help manage weight and diabetes, and your participation could contribute to important research in this area.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants 18-65 years old, inclusive
• • BMI of 25 - 40, inclusive
• • Stable body weight for two months
• Additional Inclusion Criterion for Part 3 (MD T2DM cohorts) only:
• • Participants in Part 3 should have a documented diagnosis of Type 2 Diabetes Mellitus (T2DM)
• • Participants in Part 3 should have glycated hemoglobin (HbA1c) between 7.0% and 10.0%
• Exclusion Criteria:
• • History of significant medical conditions and malignancy
• • Uncontrollable hypertension
• • History of alcoholism or drug addiction within 1 year prior to Screening
• • Current or recent participation in an investigational clinical trial